During late August a presentation at the 2018 European Society of Cardiology Congress in Munich, Germany included evidence that the SGLT-2 inhibitors Invokana, Jardiance, and Farxiga all are associated with twofold increases for lower-limb amputations when compared to GLP-1 receptor agonists diabetes drugs.
An August 25, 2018 Healio.com article, “SGLT2 inhibitor therapies may raise risk for amputation, diabetic ketoacidosis in diabetes with CVD”, provides the details.
This is second new medical study which indicates that lower extremity amputations is a drug class side effects of SGLT-2 inhibitor diabetes drugs such as Invokana, Jardiance, and Farxiga.
Earlier this month we reported that a medical study found that SGLT-2 inhibitors have a higher risk of leg, feet, and toe amputations when compared to older diabetes drugs such as sulfonylureas, metformin, and thiazolidinediones. An article setting forth the findings of this study was published online August 13, 2018 by the medical journal JAMA Internal Medicine.[Read article in full at original source]
Invokana / Farxiga / Jardiance
Free Case Evaluation
Strictly Confidential, No Obligation.